Conmana
(Icotinib)Phase 3Small molecule
Icotinib is used to treat a specific type of lung cancer called non-small cell lung cancer in patients whose cancer cells have certain mutations in a gene called EGFR.[1] Conmana is currently being investigated across 17 indications[3], with its most advanced program in Phase 3.[1]
Conmana is one of 407 small molecule programs targeting Metastasis. It is currently in Phase 3.
17
Indications
63
Total Trials
5
Active Trials
406
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Conmana
BBetta Pharmaceuticals Co., Ltd.
Phase 3
Tecentriq
RochePreclinical
Halaven
EisaiPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Adenocard
AstellasPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer14 trials
Show 11 more trials
Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer
Unknown status·PPeople's Hospital of Guangxi Zhuang Autonomous Region·Phase 2·NCT02407366·80 enrolled
Lung Cancer9 trials
Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy
Unknown status·—·Phase 2·NCT01963195·30 enrolled
Show 6 more trials
Lung Adenocarcinoma5 trials
Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation
Unknown status·—·Phase 4·NCT02283424·10 enrolled
EGFR Mutation3 trials
The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation
Unknown status·—·Phase 2·NCT02820116·67 enrolled
First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation
Unknown status·—·Phase 3·NCT02883543·330 enrolled
22 more indications
Brain Metastases2 trials
Pancreatic Cancer2 trials
First-line Treatment2 trials
Small Cell Lung Cancer2 trials
Advanced NSCLC2 trials
Adenocarcinoma2 trials
Nasopharyngeal Carcinoma2 trials
Adjuvant Therapy2 trials
Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations
Not yet recruiting·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 3·NCT06955325·270 enrolled
Triple-Negative Breast Cancer1 trial
Radiation Therapy1 trial
Esophageal Carcinoma1 trial
Non-squamous NSCLC1 trial
Prospective1 trial
Growth1 trial
Real-world Study1 trial
Neurofibromatosis1 trial
Metastasis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Icotinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Epidermal Growth Factor Receptor Erbb1 Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBetta Pharmaceuticals Co., Ltd.